Clinical trials
Brain Metastases From Non-small Cell Lung Cancer (NSCLC) clinical trials
Below are recruiting brain metastases from non-small cell lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 274 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06641609RecruitingPhase 1
Study of CFT8919 for advanced NSCLC with EGFR L858R mutation
This trial tests a new drug, CFT8919, for people with a specific type of advanced lung cancer (non-small cell lung cancer with an EGFR L858R mutation) that has stopped responding to other treatments. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06639191RecruitingEarly Phase 1
Study of a new drug for cancers expressing CD44v6
This trial tests a new radioactive drug called [177Lu]Lu-AKIR001 for patients with certain advanced cancers (like thyroid, head and neck, lung, vulvar, or cervical cancer) that have a specific protein called CD44v6 on their surface. The goal is to see if this treatment can help when standard options have stopped working.
Stockholm, Stockholm CountyAges 18 years+ - NCT06620835RecruitingPhase 2
Optimizing local treatments for ALK-positive lung cancer on brigatinib
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
BrestAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+ - NCT06616766RecruitingPhase 1/Phase 2
Study of YH42946 for advanced cancer with HER2 or EGFR changes
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Fairfax, VirginiaAges 18 years+ - NCT06582771RecruitingPhase 2
Testing sotorasib for untreated lung cancer with KRAS G12C mutation
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
Basking Ridge, New JerseyAges 18 years+ - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT06518057RecruitingPhase 2
Sparing memory during brain radiation for leptomeningeal metastases
This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05236946RecruitingPhase 3
Brain radiation timing study for gene-mutated lung cancer
This study compares giving brain radiation right away versus waiting, in people with lung cancer that has an EGFR or ALK gene change and has spread to the brain but causes no symptoms. It aims to see which approach helps control the brain cancer better and keeps quality of life stable.
Mumbai, MaharashtraAges 18–99 - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT06448572RecruitingPhase 1/Phase 2
EXL01 and nivolumab for immunotherapy-resistant lung cancer
This trial tests an investigational microbiome therapy (EXL01) combined with nivolumab (an immunotherapy) for people with advanced non-small cell lung cancer whose cancer continued to grow after standard immunotherapy and chemotherapy. The goal is to see if adding EXL01 can help the immune system fight the cancer again.
LilleAges 18 years+ - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Anchorage, AlaskaAges 18 years+ - NCT06343402RecruitingPhase 1
Study of BBO-8520 for advanced KRAS G12C lung cancer
This trial tests a new oral medication called BBO-8520 for advanced lung cancer with a specific gene change (KRAS G12C mutation). It aims to see if the drug is safe and effective, and may be combined with another drug (pembrolizumab) in some groups.
Birmingham, AlabamaAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Fountain Valley, CaliforniaAges 18 years+ - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT06295432RecruitingPhase 2
Study of two targeted drugs for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06315010RecruitingPhase 2
Repotrectinib for lung cancer with brain metastasis
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
GrazAges 18 years+ - NCT05037331Recruiting
Osimertinib for advanced EGFR-mutated lung cancer
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
SingaporeAges 21–99 - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+
Hear when a new Brain Metastases From Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain metastases from non-small cell lung cancer (nsclc)?
- Yes. Clin2 currently lists 274 recruiting brain metastases from non-small cell lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain metastases from non-small cell lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain metastases from non-small cell lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.